Explore more publications!

Asia Healthcare Industry Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.

Press releases published on September 17, 2025

WorldUpstart Expands Global Footprint to Bring Healthcare Innovation to the U.S. Market
The Brookbush Institute Publishes a NEW Article: 'Drop Sets: Comprehensive Systematic Review & Training Recommendations'
The Choroideremia Research Foundation (CRF) Marks 25 Years of Progress, Research, and Community Support
AllegroGraph Named a 2025 Trend Setting Product by KMWorld
IndoUSrare Announces 2025 Abbey Meyers Khushi Bridging RARE Award Honorees
Analgesics Volume to reach $50.7 billion by 2030, growing at a CAGR of 6.6%
Degenerative Disc Disease Treatment Volume is rising at a CAGR of 5.5% from 2023 to 2032
Liquid Dietary Supplements Volume is registering a CAGR of 4.0% from 2020 to 2027
Syringes Volume to Reach $32.39 Billion, Globally, by 2027 at 9.6% CAGR
Cancer Gene Therapy Volume is projected to reach $11.4 billion by 2030, growing at a CAGR of 23.3%
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
Alcohol Enzymes Market Size, Industry Share, Regional Forecast, 2027
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-PD-1
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
CooperCompanies Announces Expanded Share Repurchase Program

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions